These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 8535211

  • 1. Use of clodronate in multiple myeloma.
    Jantunen E, Lahtinen R, Laakso M.
    Leuk Lymphoma; 1995 Oct; 19(3-4):207-11. PubMed ID: 8535211
    [Abstract] [Full Text] [Related]

  • 2. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.
    Laakso M, Lahtinen R, Virkkunen P, Elomaa I.
    Br J Haematol; 1994 Aug; 87(4):725-9. PubMed ID: 7986713
    [Abstract] [Full Text] [Related]

  • 3. [Multiple myeloma and bone manifestations. Role of clodronate].
    Bauduer F, Delmer A.
    Bull Cancer; 1996 Jul; 83(7):542-7. PubMed ID: 8868941
    [Abstract] [Full Text] [Related]

  • 4. Treatment of painful bone lesions and hypercalcemia.
    Ascari E, Attardo-Parrinello G, Merlini G.
    Eur J Haematol Suppl; 1989 Jul; 51():135-9. PubMed ID: 2534078
    [Abstract] [Full Text] [Related]

  • 5. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications.
    Clemens MR, Fessele K, Heim ME.
    Ann Hematol; 1993 Mar; 66(3):141-6. PubMed ID: 8471660
    [Abstract] [Full Text] [Related]

  • 6. Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy.
    Merlini G, Parrinello GA, Piccinini L, Crema F, Fiorentini ML, Riccardi A, Pavesi F, Novazzi F, Silingardi V, Ascari E.
    Hematol Oncol; 1990 Mar; 8(1):23-30. PubMed ID: 2137106
    [Abstract] [Full Text] [Related]

  • 7. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.
    Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I.
    Lancet; 1992 Oct 31; 340(8827):1049-52. PubMed ID: 1357451
    [Abstract] [Full Text] [Related]

  • 8. The use of clodronate in multiple myeloma.
    Delmas PD.
    Bone; 1991 Oct 31; 12 Suppl 1():S31-4. PubMed ID: 1835398
    [Abstract] [Full Text] [Related]

  • 9. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL, Goa KL.
    Drugs; 1994 Jun 31; 47(6):945-82. PubMed ID: 7521833
    [Abstract] [Full Text] [Related]

  • 10. Bisphosphonate therapy in multiple myeloma: past, present, future.
    Jantunen E.
    Eur J Haematol; 2002 Jun 31; 69(5-6):257-64. PubMed ID: 12460229
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults.
    McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA.
    Br J Haematol; 1998 Feb 31; 100(2):317-25. PubMed ID: 9488619
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonate therapy in multiple myeloma.
    Laakso M, Jantunen E.
    Acta Oncol; 1996 Feb 31; 35 Suppl 5():55-6. PubMed ID: 9142966
    [Abstract] [Full Text] [Related]

  • 13. Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders.
    Ghinoi V, Brandi ML.
    Expert Opin Pharmacother; 2002 Nov 31; 3(11):1643-56. PubMed ID: 12437497
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B.
    Cochrane Database Syst Rev; 2012 May 16; (5):CD003188. PubMed ID: 22592688
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonates in multiple myeloma.
    Kanis JA, McCloskey EV.
    Cancer; 2000 Jun 15; 88(12 Suppl):3022-32. PubMed ID: 10898347
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonates in multiple myeloma.
    Berenson JR.
    Cancer; 1997 Oct 15; 80(8 Suppl):1661-7. PubMed ID: 9362433
    [Abstract] [Full Text] [Related]

  • 17. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
    Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, García-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD.
    J Clin Oncol; 2013 Jun 20; 31(18):2347-57. PubMed ID: 23690408
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonates in multiple myeloma.
    Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A.
    Cochrane Database Syst Rev; 2001 Jun 20; (4):CD003188. PubMed ID: 11687178
    [Abstract] [Full Text] [Related]

  • 19. [Bisphosphonates and bone metastases].
    Lortholary A, Jadaud E, Berthaud P.
    Bull Cancer; 1999 Sep 20; 86(9):732-8. PubMed ID: 10519966
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonates in multiple myeloma.
    Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A.
    Cochrane Database Syst Rev; 2002 Sep 20; (3):CD003188. PubMed ID: 12137679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.